IN PURSUIT OF YOUR CURE.™

North Carolina Symposium

Craig Moskowitz, MD Physician in Chief Sylvester Comprehensive Cancer Center Professor of Medicine, Miller School of Medicine University of Miami Health System






A Cancer Center Designated by the National Cancer Institute

Discussion Question

In which situations, if any, do you feel it would be beneficial to administer polatuzumab vedotin/R-CHP as first-line therapy for diffuse large B-cell lymphoma (DLBCL)?



POLARIX: Polatuzumab Vedotin-R-CHP vs R-CHOP in 1L DLBCL





Tilly H et al. N Engl J Med 2022;386(4):351-363; Mehta-Shah N et al. Pan Pacific Lymphoma Conference 2022.

POLARIX: Polatuzumab Vedotin-R-CHP vs R-CHOP in 1L DLBCL

			la-R-CHP (N=440)		R-CHOP N=439)					
Baseline Risk Factors	Tota N	l n	2-year Rate	n	2-year Hazard Rate Ratio		95% Wald Cl	Pola-R-CHP Better	R-CHOP Better	
Ann Arbor stage I–II III IV	99 232 548	47 124 269	89·1 80·7 72·6	52 108 279	85∙5 73∙6 66∙1	0·6 0·8 0·8	(0·2 to 1·8) (0·5 to 1·3) (0·6 to 1·1)			
Baseline LDH ≤ULN >ULN	300 575	146 291	78·9 75·4	154 284	75·6 67·2	0·8 0·7	(0.5 to 1.3) (0.5 to 1.0)	1		
No. of extranodal sites 0–1 ≥2	453 426	227 213	80·2 73·0	226 213	74·5 65·8	0·8 0·7	(0·5 to 1·1) (0·5 to 1·0)		4	
Cell-of-origin GCB ABC Unclassified Unknown	352 221 95 211	184 102 44 110	75·1 83·9 73·0 73·8	168 119 51 101	76·9 58·8 86·2 64·3	1·0 0·4 1·9 0·7	(0.7 to 1.5) (0.2 to 0.6) (0.8 to 4.5) (0.4 to 1.2)			
Double expressor by IHC DEL Non DEL Unknown	290 438 151	139 223 78	75∙5 77∙7 76∙0	151 215 73	63·1 75·7 69·8	0·6 0·9 0·8	(0·4 to 1·0) (0·6 to 1·3) (0·4 to 1·5)			
Double- or triple-hit lymphoma Yes No Unknown	45 620 214	26 305 109	69·0 76·8 78·5	19 315 105	88·9 70·3 66·4	3·8 0·7 0·6	(0·8 to 17·6) (0·5 to 1·0) (0·4 to 1·1)			
							C	r ⊷25	1 5	



Discussion Question

For patients with relapsed/refractory (R/R) DLBCL, how do you usually sequence CAR T-cell therapy, polatuzumab vedotin, tafasitamab/lenalidomide, loncastuximab tesirine and selinexor?



Lancet Haematol 2020;7:e511-22.

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda*, Marie Maerevoet*, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi, Reda Bouabdallah, Sylvain Choquet, Ronit Gurion, Brian Hill, Ulrich Jaeger, Juan Manuel Sancho, Michael Schuster, Catherine Thieblemont, Fátima De la Cruz, Miklos Egyed, Sourav Mishra, Fritz Offner, Theodoros P Vassilakopoulos, Krzysztof Warzocha, Daniel McCarthy, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Hua Chang, Yosef Landesman, Anita Joshi, Hongwei Wang, Jatin Shah, Sharon Shacham, Michael Kauffman, Eric Van Den Neste, Miguel A Canales

	ORR	CRR
All patients	36/127 (28%)	15/127 (12%)
GCB subtype	20/59 (34%)	8/59 (14%)
Non-GCB subtype	13/63 (21%)	6/63 (10%)
Unclassified	3/5 (60%)	1/5 (20%)

Maerevoet et al. J Hematol Oncol (2021) 14:111 https://doi.org/10.1186/s13045-021-01122-1

Journal of Hematology & Oncology

Open Access

LETTER TO THE EDITOR

Survival among patients with relapsed/ refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Marie Maerevoet^{1*}, Josee M. Zijlstra², George Follows³, Rene-Olivier Casasnovas⁴, J. S. P. Vermaat⁵, Nagesh Kalakonda⁶, Andre Goy⁷, Sylvain Choquet⁸, Eric Van Den Neste⁹, Brian Hill¹⁰, Catherine Thieblemont^{11,12}, Federica Cavallo¹³, Fatima De la Cruz¹⁴, John Kuruvilla¹⁵, Nada Hamad¹⁶, Ulrich Jaeger¹⁷, Paolo Caimi¹⁸, Ronit Gurion^{19,20}, Krzysztof Warzocha²¹, Sameer Bakhshi²², Juan-Manuel Sancho²³, Michael Schuster²⁴, Miklos Egyed²⁵, Fritz Offner²⁶, Theodoros P. Vassilakopoulos²⁷, Priyanka Samal²⁸, Matthew Ku²⁹, Xiwen Ma³⁰, Kelly Corona³⁰, Kamal Chamoun³⁰, Jatin Shah³⁰, Sharon Shacham³⁰, Michael G. Kauffman³⁰ and Miguel Canales³¹

	Median OS
All patients (n = 134)	9 mo
Patients with CR/PR (n = 39)	Not reached
Nonresponders (n = 95)	4.9 mo





SADAL Post-Hoc Analysis: Effect of Prior Therapy and Disease Refractoriness on the Efficacy of Selinexor

Patients	ORR, % (95% CI)	P value
Prior treatments		
2 Lines of Prior Therapies ($n = 79$)	27.8 (18.3, 39.1)	
3 or More Lines of Prior Therapies ($n = 55$)	30.9 (19.1, 44.8)	.8490
Prior ASCT (n = 40)	42.5 (27.0, 59.1)	
No Prior ASCT (n = 94)	23.4 (15.3, 33.3)	.0435
Response to Last Therapy		
PR or CR (n = 92)	35.9 (26.1, 46.5)	
No PR or CR (n $=$ 37)	16.2 (6.2, 32.0)	.0470
Primary Refractory < 6 Months (n = 55)	21.8 (11.8, 35.0)	
Primary Refractory ≥ 6 Months (n = 62)	37.1 (25.2, 50.3)	.1098




Polatuzumab Vedotin + BR in R/R DLBCL – phase 2








L-MIND: prolonged PFS in a subset of patients



Duell J et al., Haematologica 2021 Duell J et al., presented at ASCO 2021




Tafasitamab-Lenalidomide Real World Data






Qualls D et al. ASH 2022 abstract 323.

Metabolic tumor volume predicts outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with loncastuximab tesirine in the LOTIS-2 trial




SUVmax ≥ 18 (*EFS*: HR=1.65, 95%Cl 1.06-2.55, P=0.027 & *OS*: HR=1.7, 95%Cl 1.06-2.75, P=0.029) MTV ≥ 68ml (*EFS*: HR=3.02, 95%Cl 1.94-4.7, P<.0001 & *OS*: HR=3.26, 95%Cl 2.05-5.19, P<.0001) TLG ≥ 479 (*EFS*: HR=2.34, 95%Cl 1.52-3.6, P=.0001 & *OS*: HR=2.46, 95%Cl 1.54-3.91, P=.0001)

Alderuccio JP et al. ASH 2022; Abstract 2960





Chalk Talk – Craig Moskowitz, MD Three Anti-CD19 CAR T-cell Constructs are Currently FDA Approved IN PURSUIT OF YOUR CURE. for R/R DLBCL



Phase 3 Trials of CAR-T vs Auto HCT in 2L LBCL

	ZUMA-7	TRANSFORM	BELINDA	
CAR T-cell Product	Axicabtagene ciloleucel	Lisocabtagene maraleucel	Tisagenlecleucel	
CAR Construct	CD19. CD28 .CD3z	CD19. 41BB .CD3z	CD19. 41BB .CD3z	
# Enrolled	359	184	322	
Median Follow Up	24.9 months	6.2 months	10 months	
% Infused in CAR-T Arm	94%	98%	96%	
% Received Bridging in CAR-T Arm	36%	63%	83%	
% to HDT-ASCT in SOC Arm	36%	47%	33%	
% SOC Crossover to CAR-T	56%	55%	51%	
Median EFS	8.3 vs. 2 months	10.1 vs. 2.3 months	3 vs. 3 months	
Hazard Ratio	0.398 (P < 0.0001)	0.349 (P < 0.0001)	1.07 (P = 0.69)	
CR Rate	65% vs. 32%	66% vs. 39%	28% vs. 28%	
Grade ≥3 CRS / ICANS	6% / 21%	1% / 4%	5% / 3%	



Discussion Question

Based on available data, do you anticipate that bispecific antibodies will be widely used for R/R DLBCL in the near future? If so, how do you envision sequencing these drugs relative to currently available therapies?




CART or Bi-specific: What should we give first?

- CR rates to Epco/Glof: 40% and CR are durable out to 2+ years
- CR rates to CART: 50%-60% at 1 month post CART; 2/3 of CR patients that remain in CR at 1 year have not progressed
- CRS/ICANS: seen in both groups
- Easier-Bispecifics
- It is more likely that CART can salvage a bispecific failure than vice a versa

• When these 2 agents are approved I will use them before CART




Activity of Mosunetuzumab in R/R Aggressive B-NHL





Activity of Glofitamab in R/R Aggressive B-NHL

Glofitamab at RP2D in aggressive NHL^{1,2}





Pivotal Phase II Study of Glofitamab in R/R DLBCL and ≥2 prior therapies Primary Endpoint Met

Efficacy endpoint ¹	Glofitamab 2.5/10/30mg (n=155)
CR rate*	61 (39.4%)
	[95% CI: 31.6%, 47.5%]
ORR*	80 (51.6%)
	[95% CI: 43.5%, 59.7%]


- Median duration of follow-up: 12.6 months (range: 0–22)
- Responses were achieved early: median time to first CR was 42 days (95% CI: 42, 44)
- At time of primary analysis, primary endpoint met in the primary efficacy population (n=108)[†]: 35.2%
 CR rate by IRC significantly greater (p<0.0001) than 20% historical control CR rate[‡]

High CR/ORR rate at RP2D

*best response by intent-to-treat population; [†]the pivotal expansion cohort population; [‡]the historical control CR rate was pre-specified based on a meta-analysis in patients with R/R DLBCL (where most [\geq 50%] had received \geq 2 prior therapies) and compared with the CR rate in the primary efficacy-evaluable population using an exact binomial test (2-sided alpha level: 5%).



Pivotal Phase II Study of Glofitamab in R/R DLBCL and ≥2 prior therapies Durable responses maintained after cessation of therapy



Dickinson M, et al. EHA 2022 oral presentation


FDA Grants Priority Review for Bispecific Antibody Glofitamab for Relapsed or Refractory Large B-Cell Lymphoma Press Release: January 6, 2023

"The US Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted priority review for glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. LBCL is an aggressive (fast-growing) type of non-Hodgkin lymphoma (NHL) and is one of the most prevalent types of blood cancer among adults in the U.S. The FDA is expected to make a decision on approval of this novel cancer immunotherapy by 1 July 2023. If approved, glofitamab would be the first fixed-duration, off-the-shelf CD20xCD3 T-cell engaging bispecific antibody available to treat people with an aggressive lymphoma who have previously received multiple courses of treatment."

https://www.globenewswire.com/news-release/2023/01/06/2584191/0/en/FDA-grants-priority-review-to-Roche-s-bispecific-antibody-glofitamab-for-people-with-relapsed-or-refractory-large-B-cell-lymphoma.html



EPCORE NHL-1: Response to Epcoritamab in R/R DLBCL






Hutchings M, et al. *Lancet* 2021;398(10306):1157-69.

EPCORE NHL-1: Deep and Durable Responses Across Subgroups with Epcoritamab

	Overall LBCL N=157	Primary refractory n=96	CAR T– naive n=96	CAR T– exposed n=61	Refractory to prior CAR T n=46	DH/TH n=12	Non– DH/TH n=76	Non– DLBCL subtypes ^a n=30
ORR, %	63	55	69	54	46	50	63	63
CR rate, %	39	30	42	34	28	33	41	37
mDOR, mo	See update ^b	NR	12.0	9.7	NR	12.0	NR	12.0
mDOR in CR patients, mo	NR	NR	NR	NR	NR	12.0	NR	12.0
MRD-negativity rate, % (n/N)º	45 (54/119)	40 (29/72)	45 (33/74)	47 (21/45)	40 (14/35)	36 (4/11)	51 (32/63)	36 (9/25)



- As of a more recent data cutoff on June 30, 2022 (median followup, 15.7 mo):
 - An estimated 61% and 55% of responders remained in response at
 - 9 and 12 mo, respectively
 - An estimated 89% and 79% of complete responders remained in response at 9 and 12 mo, respectively



FDA Grants Priority Review to Epcoritamab for Relapsed/Refractory LBCL Press Release: November 21, 2022

The FDA has granted priority review for the biologics license application (BLA) of epcoritamab as a treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL) after 2 or more lines of therapy, according to a press release.

The application is supported by findings from the LBCL cohort of the Phase I/II EPCORE NHL-1 trial (NCT03625037) which assessed epcoritamab in a population with relapsed, progressive, or refractory CD20-positive mature B-cell non-Hodgkin lymphoma. Topline data from the trial indicated that patients experienced an overall response rate of 63.1% by independent review committee with a median duration of response of 12 months. There were few incidences of high-grade cytokine release syndrome, with 49.7% of patients experiencing the toxicity in total.



https://www.cancernetwork.com/view/fda-grants-priority-review-to-epcoritamab-for-relapsed-refractory-lbcl

Discussion Question

How do you approach first-line treatment for advanced Hodgkin lymphoma (HL), and how do patient age and risk status factor in?




How do you treat advanced stage HL?

- ABVD x 6
- Escalated BEACOPP x 4-6*
- BV-AVD x 6
- ABVD x 2 followed by an interim PET after 2 cycles to inform further therapy
- Escalated BEACOPP x 2 followed by an interim PET after 2 cycles to inform further therapy

Many studies include stage IIA poor risk and IIB: This is not advanced stage HL!




The Dilemma Of Therapy






A+AVD significantly improved OS with a 41% reduction in risk of death compared with ABVD



CI, confidence interval.

OS benefit was generally consistent across prespecified subgroups



ECOG, Eastern Cooperative Oncology Group.



How do I treat ASHL

- 1. Enroll on national study if available
- 2. Off protocol BV-AVD for stage IV and IIIB pts
- 3. Pet-adapted 3 for stage IIIA as well as stage 2B (not ASHL!)
- 4. Bulky stage II which is not ASHL! I give CMT 4-6 cycles of ABVD and ISRT

Let's remember the intergroup study does not have an arm for PET-adapted therapy; the field is moving on



Discussion Question

Do you believe camidanlumab tesirine will gain FDA approval for HL in the near future, and if so, how do you envision using it relative to other evidence-based options?



Safety – Patients with Guillain–Barré Syndrome (GBS)/polyradiculopathy

- Baseline characteristics:
 - Median age: 35y (23-68)
 - 3/8 patients had prior SCT
 - Median days since last checkpoint inhibitor: 187 (50-377)
- Median number of Cami cycles (range): 3.5 (2-7)
 - 4/8 cases presented after
 2 cycles; 3/8 had onset after
 30 days post last-dose

AE by preferred Max **Duration IVIG/PLEX/ Outcome at last** Patient grade (days) **Steroids** term assessment GBS 523 Y/Y/YOngoing at grade 1 1 4 Y/Y/N 2 GBS 43 Recovered 4 Not recovered; patient 3 GBS 50 Y/Y/Y3 died of sepsis 4 GBS 3 287 Y/N/Y Ongoing at grade 1 5 GBS 3 111 Y/Y/YOngoing at grade 1^a GBS 119 Y/N/N 6 Recovered 2 7 Polyneuropathy^b, 72 Y/N/Y Recovered 4 Meningitis, Facial paralysis, SIADH 8 Radiculopathy 2 165 Y/Y/YRecovered

Summary of Patients with GBS/polyradiculopathy

Data cut off: November 1, 2021

^a Also received rituximab with clinical improvement. ^b Verbatim: polyradiculoneuritis.

IVIG, intravenous immunoglobulin; PLEX, plasma exchange; SCT, stem cell transplant; SIADH, syndrome of inappropriate secretion of antidiuretic hormone.



Camidanlumab tesirine

The book is closed: will never get approved



Lymphoma Service-Sylvester Comprehensive Cancer Center, University of Miami Health System

- Izidore Lossos
- Juan Alderuccio
- Alvaro Alencar
- Georgio Pongas
- Juan Ramos
- Joe Rosenblatt
- Jonathan Schatz
- Craig Moskowitz





A Cancer Center Designated by the National Cancer Institute



Special thanks to the Lymphoma Service at MSKCC